These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16288902)

  • 1. Experience using MedDRA for global events coding in HIV clinical trials.
    Tonéatti C; Saïdi Y; Meiffrédy V; Tangre P; Harel M; Eliette V; Dormont J; Pierre Aboulker J
    Contemp Clin Trials; 2006 Feb; 27(1):13-22. PubMed ID: 16288902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. About the necessity to manage events coded with MedDRA prior to statistical analysis: proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE.
    Journot V; Tabuteau S; Collin F; Molina JM; Chene G; Rancinan C;
    Contemp Clin Trials; 2008 Mar; 29(2):95-101. PubMed ID: 17613282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of automated signal generation in pharmacovigilance using a knowledge-based approach.
    Bousquet C; Henegar C; Louët AL; Degoulet P; Jaulent MC
    Int J Med Inform; 2005 Aug; 74(7-8):563-71. PubMed ID: 15955732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods and pitfalls in searching drug safety databases utilising the Medical Dictionary for Regulatory Activities (MedDRA).
    Brown EG
    Drug Saf; 2003; 26(3):145-58. PubMed ID: 12580645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions.
    Bousquet C; Lagier G; Lillo-Le Louët A; Le Beller C; Venot A; Jaulent MC
    Drug Saf; 2005; 28(1):19-34. PubMed ID: 15649103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building an ontology of adverse drug reactions for automated signal generation in pharmacovigilance.
    Henegar C; Bousquet C; Lillo-Le Louët A; Degoulet P; Jaulent MC
    Comput Biol Med; 2006; 36(7-8):748-67. PubMed ID: 16185681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
    Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
    J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using MedDRA: implications for risk management.
    Brown EG
    Drug Saf; 2004; 27(8):591-602. PubMed ID: 15154830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART.
    Brown EG
    Drug Saf; 2002; 25(6):445-52. PubMed ID: 12071782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validating a Framework for Coding Patient-Reported Health Information to the Medical Dictionary for Regulatory Activities Terminology: An Evaluative Study.
    Brajovic S; Blaser DA; Zisk M; Caligtan C; Okun S; Hall M; Pamer CA
    JMIR Med Inform; 2018 Aug; 6(3):e42. PubMed ID: 30131314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serious adverse events with infliximab: analysis of spontaneously reported adverse events.
    Hansen RA; Gartlehner G; Powell GE; Sandler RS
    Clin Gastroenterol Hepatol; 2007 Jun; 5(6):729-35. PubMed ID: 17481964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping of the WHO-ART terminology on Snomed CT to improve grouping of related adverse drug reactions.
    Alecu I; Bousquet C; Mougin F; Jaulent MC
    Stud Health Technol Inform; 2006; 124():833-8. PubMed ID: 17108616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Edgerly M; Fojo T
    J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The medical dictionary for regulatory activities (MedDRA).
    Brown EG; Wood L; Wood S
    Drug Saf; 1999 Feb; 20(2):109-17. PubMed ID: 10082069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MedDRA and pharmacovigilance: a complex and little-evaluated tool.
    Prescrire Int; 2016 Oct; 25(175):247-250. PubMed ID: 30645835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM).
    Yokotsuka M; Aoyama M; Kubota K
    Int J Med Inform; 2000 Jul; 57(2-3):139-53. PubMed ID: 10961570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A reduced frequency visit schedule underreports adverse events that resulted in dose modifications or treatment discontinuations in HIV/AIDS clinical trials: ACTG DACS 207.
    Kendall MA; Andersen JW; van der Horst C
    Contemp Clin Trials; 2006 Jun; 27(3):287-94. PubMed ID: 16545621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.